

Company Number: 650760

Ashdown Pharmacy (Limerick) Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

Ashdown Pharmacy (Limerick) Limited

CONTENTS

	Page
Director and Other Information	3
Director's Responsibilities Statement	4
Statement of Financial Position	5 - 6
Statement of Changes in Equity	7
Notes to the Financial Statements	8 - 11

Ashdown Pharmacy (Limerick) Limited
DIRECTOR AND OTHER INFORMATION

Director	Mary Guiney
Company Secretary	Ciaran Cunningham
Company Number	650760
Business Address	No 3 Ashbourne Avenue South Circular Road Limerick
Accountants	L.V. Hogan & Company Limited Chartered Accountants Monaleen Road Casteltroy Limerick
Bankers	Bank of Ireland 125 O'Connell Street Limerick Republic of Ireland

Ashdown Pharmacy (Limerick) Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2025

The director made the following statement in respect of the unaudited financial statements:

"General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Statement of Financial Position, the Statement of Changes in Equity and the related notes:

The director approves these financial statements and confirms that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that they have made available to L.V. Hogan & Company Limited, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 December 2025."

Signed on behalf of the board

Ciaran Cunningham
Company Secretary

23 February 2026

Mary Guiney
Director

23 February 2026

Ashdown Pharmacy (Limerick) Limited
STATEMENT OF FINANCIAL POSITION

as at 31 December 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Property, plant and equipment	5	<u>54,932</u>	<u>76,417</u>
Current Assets			
Inventories	6	118,639	100,000
Receivables	7	80,742	71,446
Cash and cash equivalents		<u>313,960</u>	<u>201,473</u>
		<u>513,341</u>	<u>372,919</u>
Payables: amounts falling due within one year	8	<u>(96,608)</u>	<u>(94,602)</u>
Net Current Assets		<u>416,733</u>	<u>278,317</u>
Total Assets less Current Liabilities		471,665	354,734
Payables:			
amounts falling due after more than one year	9	<u>(23,540)</u>	<u>(23,782)</u>
Net Assets		<u><u>448,125</u></u>	<u><u>330,952</u></u>
Equity			
Called up share capital presented as equity		100	100
Retained earnings		<u>448,025</u>	<u>330,852</u>
Equity attributable to owners of the company		<u><u>448,125</u></u>	<u><u>330,952</u></u>

Ashdown Pharmacy (Limerick) Limited

STATEMENT OF FINANCIAL POSITION

as at 31 December 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Ashdown Pharmacy (Limerick) Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 23 February 2026 and signed on its behalf by:

Ciaran Cunningham
Company Secretary

Mary Guiney
Director

Ashdown Pharmacy (Limerick) Limited
STATEMENT OF CHANGES IN EQUITY

as at 31 December 2025

	Called up share capital €	Retained earnings €	Total €
At 1 January 2024	100	224,474	224,574
Profit for the financial year	-	106,378	106,378
At 31 December 2024	100	330,852	330,952
Profit for the financial year	-	117,173	117,173
At 31 December 2025	100	448,025	448,125

Ashdown Pharmacy (Limerick) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

1. General Information

Ashdown Pharmacy (Limerick) Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 650760. The registered office of the company is. The principal activity of the company is the operation of a retail pharmacy The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Revenue

Revenue comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 12.5% Straight line
Motor vehicles	- 25% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Leasing and hire purchases

Property, plant and equipment held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Statement of Financial Position at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Income Statement.

Inventories

Inventories are valued at the lower of cost and net realisable value. Inventories are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing inventories to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other receivables

Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Ashdown Pharmacy (Limerick) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other payables

Trade and other payables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of property, plant and equipment	21,485	21,483
(Profit)/loss on disposal of property, plant and equipment	-	2,553
Government grants received	(1,903)	(8,232)
	<u><u> </u></u>	<u><u> </u></u>

4. Employees

The average monthly number of employees, including director, during the financial year was 8, (2024 - 8).

	2025	2024
	Number	Number
General	8	8
	<u><u> </u></u>	<u><u> </u></u>

Ashdown Pharmacy (Limerick) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

5. Property, plant and equipment

	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost			
At 1 January 2025	57,964	68,770	126,734
At 31 December 2025	57,964	68,770	126,734
Depreciation			
At 1 January 2025	30,172	20,145	50,317
Charge for the financial year	7,245	14,240	21,485
At 31 December 2025	37,417	34,385	71,802
Carrying amount			
At 31 December 2025	20,547	34,385	54,932
At 31 December 2024	27,792	48,625	76,417

6. Inventories

	2025 €	2024 €
Finished goods and goods for resale	118,639	100,000

The replacement cost of stock did not differ significantly from the figures shown.

7. Receivables

	2025 €	2024 €
Trade receivables	46,490	41,377
Other debtors	32,955	27,142
Taxation	1,297	2,927
	80,742	71,446

8. Payables

	2025 €	2024 €
Net obligations under finance leases and hire purchase contracts	-	7,647
Trade payables	76,126	71,119
Taxation	21,554	15,836
Accruals	(1,072)	-
	96,608	94,602

Ashdown Pharmacy (Limerick) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

9. Payables	2025	2024
Amounts falling due after more than one year	€	€
Finance leases and hire purchase contracts	21,665	21,665
Director's loan accounts	1,875	2,117
	<u>23,540</u>	<u>23,782</u>
Net obligations under finance leases and hire purchase contracts		
Repayable within one year	-	7,647
Repayable between one and five years	21,665	21,665
	<u>21,665</u>	<u>29,312</u>
10. Income Statement		
	2025	2024
	€	€
At 1 January 2025	330,852	224,474
Profit for the financial year	117,173	106,378
	<u>448,025</u>	<u>330,852</u>
11. Capital commitments		
The company had no material capital commitments at the financial year-ended 31 December 2025.		
12. Director's remuneration and transactions	2025	2024
	€	€
Remuneration	54,491	51,294
Pension contributions	-	1,040
	<u>54,491</u>	<u>52,334</u>
The following amounts are repayable to the director:		
	2025	2024
	€	€
	-	(883)
	<u> </u>	<u> </u>
13. Events After the End of the Reporting Period		
There have been no significant events affecting the company since the financial year-end.		
14. Approval of financial statements		
The financial statements were approved and authorised for issue by the board on 23 February 2026.		